Skip to content

Effect of potassium rich diet in patients with ulcerative colitis

Efficacy of potassium rich diet (coconut water) as add on therapy in inducing remission in patients with mild to moderate ulcerative colitis: a randomized control trial

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2019/03/018217
Enrollment
100
Registered
2019-03-20
Start date
Unknown
Completion date
Unknown
Last updated
2023-02-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K638- Other specified diseases of intestine

Interventions

Intervention1: Intervention group: Patients will receive 400 ml of coconut water daily (250 mg potassium/100 ml) in addition to oral 5-ASA (2.4-3.6 gm/day) for 8 weeks. In a previous study patients in

Sponsors

Dept of Gastroenterology
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patients who are confirmed cases of mild ulcerative colitis (of any disease extent) as assessed by Mayo score (4-6), within 1 week of relapse 2.Age: 18 â?? 70 years of either gender 3.Patients on stable dose of mesalamine for past 4 weeks 4.Patients on stable dose of azathiopurine/ 6-mercaptopurine for past 6 months 5.Ready to participate

Exclusion criteria

Exclusion criteria: 1.H/O of oral steroids in the past 4 weeks 2.H/O or oral antibiotics within past 2 weeks 3.H/O topical therapy within 1 week 4.Patients with severe disease activity 5.Patients with fulminant colitis requiring hospitalization 6.Patients who have had surgery 7.Patients with Crohnâ??s colitis 8.Patients with concomitant GI infection 9.Patients on drugs that can affect potassium homeostasis (ACE-inhibitors, angiotensin receptor blockers, aldosterone antagonists) 10.Patients with comorbidities like acute myocardial infarction, chronic kidney disease or chronic liver disease or any other condition which precludes high potassium diet 11.Patients with significant hepatic, renal, endocrine, respiratory, neurologic, or cardiovascular diseases will also be excluded 12.Pregnant, lactating females

Design outcomes

Primary

MeasureTime frame
1.Clinical remission at 8 weeks, defined as Mayo score â?¤2 with all sub-scores â?¤1.Timepoint: at 8 weeks

Secondary

MeasureTime frame
1.Clinical response at 8 weeks, defined as reduction in Mayo score by more than 3 points or by 30 percent reduction in Mayo score from baseline. 2.Treatment failure, defined as increase in Mayo score by more than 3 points with all sub scores more than 1. 3.Adverse events at 8 weeks Timepoint: At 8 weeks

Countries

India

Contacts

Public ContactDrVineet Ahuja

All India Institute of medical Sciences

vineet.aiims@gmail.com01126593300

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026